Lambros Charles Tselikas MD, Abstract Co-Author: Nothing to Disclose

Frederic Pigneur MD, Abstract Co-Author: Nothing to Disclose

Marion Roux, Abstract Co-Author: Nothing to Disclose

Vincent Roche, Abstract Co-Author: Nothing to Disclose

Laurence Baranes MD, Presenter: Nothing to Disclose

Julien Calderaro, Abstract Co-Author: Nothing to Disclose

Charlotte Costentin, Abstract Co-Author: Nothing to Disclose

Damien Medico, Abstract Co-Author: Nothing to Disclose

Marjan Djabbari, Abstract Co-Author: Nothing to Disclose

Alexis Laurent, Abstract Co-Author: Nothing to Disclose

Ariane Mallat, Abstract Co-Author: Nothing to Disclose

Alain Rahmouni MD, Abstract Co-Author: Nothing to Disclose

Alain Luciani MD, PhD, Abstract Co-Author: Nothing to Disclose

To compare the added value of contrast-enhanced ultrasound (CEUS) and delayed hepatobiliary phase (HBP) imaging using Gd-BOPTA enhanced MRI in patients with atypical benign hepatocellular lesions (BLT).

Sixty four BLT -37 focal nodular hyperplasia (FNH) and 27 hepatocellular adenomas (HCA)– with atypical presentation on liver MR using extracellular Gd chelates (EC-MRI) in 41 patients where retrospectively included in this IRB approved study. All patients underwent HBP MRI and CEUS. Two radiologists independently reviewed 2 sets of images: set 1 EC-MRI and HBP MRI; set 2 EC-MRI and CEUS. All HCA and 38% of all FNH were documented on pathology, the remaining FNH being diagnosed in board decisions and a median 18 months follow-up. Sensitivity (Se) specificity (Spe) were compared between the two sets, and subgroup analysis according to lesion’s size were performed.

Regardless of lesion size, the respective Se and Spe of both data sets were not statistically different (94 and 100% vs. 78 and 92% respectively; p=0.11 and p=0.48). For lesions larger than 35mm, although both sets had similar excellent specificity (100%, p = 1) the sensitivity was higher for EC- MRI+HBP set (100% vs. 33%; p=0.04).

Although the overall performances of EC-MRI + CEUS and EC-MRI + HBP MRI are similar, the use of HBP should be advocated over CEUS in larger than 35mm large benign hepatocellular lesions.

Size influences HBP and CEUS diagnostic performances. the use of HBP should be advocated over CEUS in larger than 35mm large benign hepatocellular lesions.

Tselikas, L, Pigneur, F, Roux, M, Roche, V, Baranes, L, Calderaro, J, Costentin, C, Medico, D, Djabbari, M, Laurent, A, Mallat, A, Rahmouni, A, Luciani, A, Diagnostic Management of Benign Hepatocellular Lesions Imaged atMR - Hepatobiliary Phase versus CEUS.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14005806.html